Alvogen Settles With Celgene Over US Revlimid

 
• By Grace Montgomery

Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.

DollarSign
Alvogen can sell generic lenalidomide in the US after 2022 • Source: Shutterstock

More from Generics

More from Products